Ebrahim Sabri Mahmoud - Infectious Diseases

Author Information

Ebrahim Sabri Mahmoud is a distinguished researcher affiliated with the Division of Infectious Diseases, Department of Medicine, at the Ministry of National Guard-Health Affairs in Riyadh, Saudi Arabia. His expertise in infectious diseases is reflected in his extensive research, particularly in the context of the COVID-19 pandemic, where he has contributed significantly to understanding treatment efficacy and clinical outcomes.

Research Contributions

Dr. Ebrahim Sabri Mahmoud has made substantial contributions to the study of infectious diseases, with a particular focus on COVID-19. His research includes a variety of clinical trials and observational studies aimed at evaluating the efficacy of antiviral drugs like favipiravir and hydroxychloroquine, understanding the clinical characteristics and outcomes of diseases such as candidemia, and developing predictive models for patient outcomes using machine learning. His work not only advances scientific knowledge but also informs clinical practices in managing infectious diseases.

Aliases

Throughout his career, Dr. Mahmoud has been referenced by several aliases, including Ebrahim Mahmoud, Ebrahim S. Mahmoud, and Ebrahimi Mahmoud. These variations typically appear in academic publications and reflect different spellings or abbreviations of his name.

Publication and Citation Metrics

Metric	Value
Total Citation Count	776
H-index	9
Paper Count	32

Publications:

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

DOI: 10.1016/j.cmi.2021.12.026

Year: 2022

Clinical characteristics and outcome of candidemia: Experience from a tertiary referral center in Saudi Arabia

DOI: 10.4103/sjmms.sjmms_625_21

Year: 2022

Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19.

DOI: 10.1172/JCI147834

Year: 2021

Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia

DOI: 10.1016/j.jiph.2021.11.017

Year: 2021

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

DOI: 10.1007/s40121-021-00496-6

Year: 2021

Developing Machine-Learning Prediction Algorithm for Bacteremia in Admitted Patients

DOI: 10.2147/IDR.S293496

Year: 2021

Infections and patterns of antibiotic utilization in support and comfort care patients: A tertiary care center experience.

DOI: 10.1016/j.jiph.2021.05.002

Year: 2021

Early Prediction of COVID-19 Ventilation Requirement and Mortality from Routinely Collected Baseline Chest Radiographs, Laboratory, and Clinical Data with Machine Learning

DOI: 10.2147/JMDH.S322431

Year: 2021

Non-SARS Non-MERS Human Coronaviruses: Clinical Characteristics and Outcome

DOI: 10.3390/pathogens10121549

Year: 2021

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT): An Open-Label, Multicentre, Randomised, Controlled Trial

DOI: 10.2139/SSRN.3829663

Year: 2021

What is Chlamydia?

What Role Do Respiratory Droplets Play in Super-Spreading Events?

Can Targeting Metabolic Pathways Serve as a Therapeutic Strategy?

What should be done upon return from travel?

What is the Global Impact of Zika Virus?

What is the Global Impact of Malaria?

Are There Vaccines Available for Diseases Transmitted by Aedes Aegypti?

Can the Immune System Overreact?

What Are the Outcomes of Host-Pathogen Interactions?

When to Seek Medical Advice?

Partnered Content Networks

Relevant Topics